Patient P-02323

Synthetic patientMETA-24 · Day 168 · 55–64 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −24% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 74 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 75 GI-04 recommended — GI Support Protocol GI-04
Day 76 Patient accepted — Started GI-04 in the companion
Day 84 GI symptom burden −34% vs expected — GI Support Protocol GI-04
Day 84 ME-01 recommended — Monitoring Escalation ME-01
Day 85 Patient accepted — Started ME-01 in the companion
Day 88 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 90 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 74.

Primary contributors, last 14 days

Toxicity+13
GI instability+7
Treatment adherence-7
Nutritional resilience-6
Inflammatory activity+3

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −24%
GI Support Protocol GI-04Day 75
Result: symptom burden −34%
Monitoring Escalation ME-01Day 84
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

66%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

25 min

stable · 0.0 vs previous 14 d

Sleep duration

Wearable

5.8 h

stable · -0.2 vs previous 14 d

Energy level

Daily log

2.4/10

worsening · -0.5 vs previous 14 d

Steps

Wearable

3,032

stable · +58 vs previous 14 d

GI burden

Companion

48.7/100

worsening · +3.9 vs previous 14 d

Adherence

Companion

51.6 %

stable · -1.7 vs previous 14 d

Sleep quality

Wearable

33.4/100

worsening · -3.7 vs previous 14 d

Glucose, CGM daily mean

CGM

138 mg/dL

stable · +1.2 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 29 from the failing basin, 64 from restoration.

Would help

SC-12 Supportive Compound
68% improved among 25 similar · onset 6 d · confidence 78%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 78%
DT-01 Dosing / Timing Recommendation
83% improved among 6 similar · onset 5 d · confidence 78%
More protein
GI -4.9 next day on high-intake days · n 16

Would not help

Keep fat low
GI +4.2 next day on high-intake days · n 24
Keep simple carbs low
GI +3.9 next day on high-intake days · n 25
Keep caffeine low
GI +3.7 next day on high-intake days · n 24

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-4.9supporter · 95%
Dietary fat load
+4.2detractor · 95%
Simple carbohydrates
+3.9detractor · 95%
Caffeine
+3.7detractor · 95%
Ultra-processed food
+3.1detractor · 94%
Insoluble fibre
+2.8detractor · 79%
Alcohol
-1.1no signal · 27%
Histamine load
+0.9no signal · 22%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 47
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 49 and rising
- WearableSleep 5.8 h, below personal baseline
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 52
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 32/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓40
- Wearable3,032 steps/day
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.1 · butyrate capacity 32/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 55 ms
Sleep: 5.2 h
Steps: 2,583
Resting HR: 67 bpm

Daily log: GI score 49, nutritional resilience 47, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02051	45%	S14	GI-04	improved	45
P-02328	44%	S14	GI-04	improved	42
P-02255	43%	S14	GI-04	improved	43
P-02234	42%	S14	GI-04	improved	36
P-02106	41%	S14	GI-04	improved	44
P-02108	41%	S14	GI-04	improved	43
P-02103	40%	S14	GI-04	improved	46
P-02310	40%	S14	GI-04	improved	35
P-02168	38%	S15	GI-04	improved	42
P-02002	37%	S14	GI-04	improved	47
P-02504	37%	S14	GI-04	improved	52
P-02176	36%	S14	GI-04	improved	52